The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica
Open accessAbstract
Neuromyelitis optica (NMO) is an autoimmune disease targeting aquaporin 4 (AQP4), localized mainly at the astrocytic foot processes. Loss of AQP4 and glial fibrillary acidic protein (GFAP) was reported, but the pathological significance of astrocytopathy is still controversial. Here we show that active lesions in NMO display a wide spectrum of pathology even within a single tissue block of an individual patient. We have distinguished six different lesion types. The first reflects complement deposition at the surface of astrocytes, associated with granulocyte infiltration and astrocyte necrosis and followed by demyelination, global tissue destruction and the formation of cystic, necrotic lesions (lesion type 2). Such destructive lesions lead to Wallerian degeneration in lesion-related tracts (lesion type 3). Around active NMO lesions AQP4 may selectively be lost in the absence of aquaporin 1 (AQP1) loss or other structural damage (lesion type 4). Another pattern is characterized by clasmatodendrosis of astrocytes, defined by cytoplasmic swelling and vacuolation, beading and dissolution of their processes and nuclear alterations resembling apoptosis, which was associated with internalization of AQP4 and AQP1 and astrocyte apoptosis in the absence of complement activation. Such lesions give rise to extensive astrocyte loss, which may occur in part in the absence of any other tissue injury, such as demyelination or axonal degeneration (lesion type 5). Finally, lesions with a variable degree of astrocyte clasmatodendrosis are found, which show plaque-like primary demyelination that is associated with oligodendrocyte apoptosis, but with preservation of axons (lesion type 6). In active multiple sclerosis (MS) lesions astrocytes reveal changes of reactive protoplasmatic or fibrillary gliosis. Only in a subset of lesions, in patients with aggressive disease, loss of AQP4 is observed in the initial stage of their formation, which is associated with retraction of astrocyte processes in the absence of complement deposition, granulocyte infiltration or loss of AQP1 or astrocytes. Our data underline the primary assault of astrocytes in NMO lesions, but also indicate that different mechanisms of tissue injury operate in parallel in the same patient and even within the same lesion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
Lennon, V. A., Wingerchuk, D. M., Kryzer, T. J., Pittock, S. J., Lucchinetti, C. F., Fujihara, K., Nakashima, I., & Weinshenker, B. G. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17551-x · Cited by 3,239 · cited 1×
“Recently, auto-antibodies directed against the astrocyte water channel aquaporin 4 (AQP4) have been discovered in NMO patients, which turned out to be a highly specific and sensitive paraclinical diagnostic marker of the disease [11, 25, 26].”
BackgroundSelf-citationGlycolytic oligodendrocytes maintain myelin and long-term axonal integrity
Fünfschilling, U., Supplie, L. M., Mahad, D., Boretius, S., Saab, A. S., Edgar, J., Brinkmann, B. G., Kassmann, C. M., Tzvetanova, I. D., Möbius, W., et al. (2012) · Nature · doi:10.1038/nature11007 · Cited by 1,523 · cited 1×
“Energy demand of oligodendrocytes and axons is in part provided by astrocytes, transferring lactate through gap junctions to oligodendrocytes [9].”
BackgroundMitochondrial defects in acute multiple sclerosis lesions
Mahad, D., Ziabreva, I., Lassmann, H., & Turnbull, D. (2008) · Brain · doi:10.1093/brain/awn105 · Cited by 406 · cited 1×
“Since demyelination in a subset of MS lesions is associated with oxidative damage, mitochondrial injury [29] and a state of virtual hypoxia [1], it could also be that such lesions are induced”
BackgroundSelf-citationHöftberger, R., Fink, S., Aboul‐Enein, F., Botond, G., Olah, J., Berki, T., Ovadi, J., Lassmann, H., Budka, H., & Kovacs, G. G. (2010) · Glia · doi:10.1002/glia.21054 · Cited by 79 · cited 1×
“TPPP/p25 Rabbit (pAB) Tubulin polymerization promoting protein; Oligodendrocytes 1:250 St (E) [15]”
BackgroundSelf-citation
Cited by
Lassmann, H. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a028936 · Cited by 937
Self-citationMyelin in the Central Nervous System: Structure, Function, and Pathology
Stadelmann, C., Timmler, S., Barrantes-Freer, A., & Simons, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00031.2018 · Cited by 728
Jarius, S., Paul, F., Weinshenker, B. G., Levy, M., Kim, H. J., & Wildemann, B. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0214-9 · Cited by 478
Astrocytes in human central nervous system diseases: a frontier for new therapies
Verkhratsky, A., Butt, A., Li, B., Illes, P., Zorec, R., Semyanov, A., Tang, Y., & Sofroniew, M. V. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01628-9 · Cited by 428
The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica
Lucchinetti, C. F., Guo, Y., Popescu, B. F. G., Fujihara, K., Itoyama, Y., & Misu, T. (2014) · Brain Pathology · doi:10.1111/bpa.12099 · Cited by 414
Self-citation
Metadata
- Authors
- Misu, T., Höftberger, R., Fujihara, K., Wimmer, I., Takai, Y., Nishiyama, S., Nakashima, I., Konno, H., Bradl, M., Garzuly, F., Itoyama, Y., Aoki, M., & Lassmann, H.
- Venue
- Acta Neuropathologica
- Published
- 2013-04-12
- Volume
- 125
- Issue
- 6
- Pages
- 815-827
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2082669552
- Cited by
- 232
- References
- 4
- FWCI
- 17.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.